The 2022 Tandem Meetings | Day 30 SUVmax to predict progression in patients with LBCL achieving PR after CAR-T therapy
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the results of a study investigating clinical features associated with a higher risk of progression in patients with large B-cell lymphoma (LBCL) who achieve a partial response (PR) with axicabtagene ciloleucel (axi-cel). The study found that a maximum standardized uptake volume (SUVmax) above 10 on day 30 was associated with a high risk of progression. This data supports the use of subsequent consolidation therapy in patients with a high SUVmax on day 30. An ongoing study is investigating the use of loncastuximab tesirine with an anti-CD19 antibody-drug conjugate as a consolidation strategy for patients who achieve a PR at day 30. These studies will also help to better understand the biology of these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
